Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | LIFR | P42702 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114750 | 0.99 | NR1H4 (0.98) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| Trichloroethylene SCHEMBL4951133 | 0.95 | NR1H4 (0.91) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| SCHEMBL2113248 | 0.94 | NR1H4 (1.00) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| Tromethamine SCHEMBL2114846 | 0.94 | NR1H4 (0.88) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| SCHEMBL2116568 | 0.92 | NR1H4 (0.86) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| SCHEMBL2116096 | 0.92 | NR1H4 (0.85) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| SCHEMBL2113528 | 0.92 | NR1H4 (0.84) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| SCHEMBL2114752 | 0.92 | NR1H4 (0.84) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| SCHEMBL2003273 | 0.88 | NR1H4 (1.00) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 | |
| SCHEMBL2000395 | 0.88 | NR1H4 (1.00) | NR1H4CYP1A2CYP2C9NR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | claimed |
| EP-1962838-B1 | FARNESOID X RECEPTOR AGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-28 | — | — | EP | claimed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | claimed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | claimed |
| EP-1962838-A2 | FARNESOID X RECEPTOR AGONISTS | Smithkline Beecham Corporation (US) | 2008-09-03 | — | — | EP | claimed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | claimed |
| EP-4090327-B1 | USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS | INST NAT SANTE RECH MED (FR) | 2025-03-05 | — | — | EP | disclosed |
| US-20240216364-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | ENYO PHARMA (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240100125-A1 | SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-03-28 | — | — | US | disclosed |
| EP-4329761-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | ENYO Pharma (FR) | 2024-03-06 | — | — | EP | disclosed |
| CN-117320722-A | Use of FXR agonists as combination therapies to strongly potentiate the effects of TLR3 agonists | 埃尼奥制药公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117202905-A | Synergistic effects of FXR agonist and IFN for the treatment of HBV infection | 埃尼奥制药公司 | 2023-12-08 | — | — | CN | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1962838-A2 | FARNESOID X RECEPTOR AGONISTS | Smithkline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885CYP1A2 163/4885CYP2C9 347/4885 |
| US-20240100125-A1 | SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION | NR1H4, IFNG, IFNAR1 | NR1H4 1/4885CYP1A2 903/4885CYP2C9 1615/4885 |
| US-20240216364-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | TLR3, NR1H4, TLR9 | NR1H4 2/4885CYP1A2 3582/4885CYP2C9 4745/4885 |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885CYP1A2 163/4885CYP2C9 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.